IMDYLLTRA

This brand name is authorized in Lithuania.

Active ingredients

The drug IMDYLLTRA contains one active pharmaceutical ingredient (API):

1	Tarlatamab UNII 74X82ST8Q1 - TARLATAMAB
	Tarlatamab is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager that binds to DLL3 expressed on the surface of tumour cells and CD3 expressed on the surface of T-cells. The bispecific binding of tarlatamab to T-cells and DLL3-positive tumour cells triggers T-cell activation, production of inflammatory cytokines, and release of cytotoxic proteins, which results in redirected lysis of tumour cells.
	Read more about Tarlatamab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
IMDYLLTRA Powder for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX33		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX33

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
LT	Valstybinė vaistų kontrolės tarnyba	1107189, 1107190